Join Growin Stock Community!

Maravai lifesciences holdings, inc.MRVI.US Overview

US StockHealthcare
(No presentation for MRVI)
My Watchlist

Ticker

Value

empty

There is no following symbol in this watchlist.

MRVI AI Insights

MRVI Overall Performance

MRVI AI Analysis & Strategy

AI Strategy

Browsing restrictions can be lifted for a fee.

MRVI Recent Performance

-0.28%

Maravai lifesciences holdings, inc.

0.05%

Avg of Sector

-0.31%

S&P500

MRVI PowerScanner

Introduction >>

Power Squeeze

Surfing Trend

1 Day

1 Week

1 Month

MRVI Key Information

MRVI Financial Forecast

chart

Browsing restrictions can be lifted for a fee.

QuarterlyEPS ForecastQoQMaxMin
2026Q1
2026Q2
2026Q3
2026Q4
2027Q1

MRVI Profile

Maravai LifeSciences Holdings, Inc., a life sciences company, provides products to enable the development of drug therapies, diagnostics, novel vaccines, and support research on human diseases in the United States and internationally. The company's products address the key phases of biopharmaceutical development and include nucleic acids for diagnostic and therapeutic applications, antibody-based products to detect impurities during the production of biopharmaceutical products, and products to detect the expression of proteins in tissues of various species. It operates in two segments, Nucleic Acid Production and Biologics Safety Testing. The Nucleic Acid Production segment manufactures and sells products for use in the fields of gene therapy, nucleoside chemistry, oligonucleotide therapy, and molecular diagnostics, including reagents used in the chemical synthesis, modification, labelling, and purification of deoxyribonucleic acid (DNA) and ribonucleic acid (RNA). This segment also offers messenger RNA, oligonucleotides, and oligonucleotide building blocks, as well as plasmid DNA and CleanCap capping technology. The Biologics Safety Testing segment sells analytical products for use in biologic manufacturing process development, including custom product-specific development antibody and assay development services. This segment also provides HCP ELISA kits, other bioprocess impurity and contaminant ELISA kits, ancillary reagents, and custom services. The company serves biopharmaceutical companies, and other biopharmaceutical and life sciences research companies; and academic research institutions and in vitro diagnostics companies. Maravai LifeSciences Holdings, Inc. was incorporated in 2020 and is headquartered in San Diego, California.

Price of MRVI

MRVI FAQ

This disclaimer is provided by TradingValley Inc. and includes any messages, news, research, analysis, prices or other information provided by the Company's website, the application "Growin App" and other services provided through the Company's website. It is only general market information for educational and investment decision-making reference, and does not constitute any investment advice. View Growin Disclaimer

MRVI Earnings Table

Unit : USD

QTRNon-GAAP EPSEPS YoYEPS Surprise %SalesSales YoYSales Surprise %NPM
Current
2025Q4
2025Q3
2025Q2
2025Q1
METRIC
VALUE
vs. INDUSTRY
EPS (TTM)
-0.90
PE Ratio (TTM)
-
Forward PE
-
PS Ratio (TTM)
7.02
PB Ratio
2.11
Price-to-FCF
-
METRIC
VALUE
vs. INDUSTRY
Gross Margin
18.30%
Net Margin
-70.41%
Revenue Growth (YoY)
-28.34%
Profit Growth (YoY)
-68.62%
3-Year Revenue Growth
-37.55%
3-Year Profit Growth
-56.07%
METRIC
VALUE
vs. INDUSTRY
EPS (TTM)
-0.90
PE Ratio (TTM)
-
Forward PE
-
PS Ratio (TTM)
7.02
PB Ratio
2.11
Price-to-FCF
-
Gross Margin
18.30%
Net Margin
-70.41%
Revenue Growth (YoY)
-28.34%
Profit Growth (YoY)
-68.62%
3-Year Revenue Growth
-37.55%
3-Year Profit Growth
-56.07%

  • When is MRVI's latest earnings report released?

    The most recent financial report for Maravai lifesciences holdings, inc. (MRVI) covers the period of 2025Q4 and was published on 2025/12/31. This report is prepared according to IFRS/US GAAP standards and includes key financial indicators—Revenue, Profitability, Cash Flow, and Capital Structure. This information is essential for investors evaluating MRVI's short-term business performance and financial health. For the latest updates on MRVI's earnings releases, visit this page regularly.

  • What is the operating profit of MRVI?

    According to the latest financial report, Maravai lifesciences holdings, inc. (MRVI) reported an Operating Profit of -58.8M with an Operating Margin of -117.91% this period, representing a decline of 51.69% compared to the same period last year. Operating Profit reflects the company's core business efficiency and cost control, making it a key indicator for evaluating operational strength and profitability.

  • How is MRVI's revenue growth?

    In the latest financial report, Maravai lifesciences holdings, inc. (MRVI) announced revenue of 49.87M, with a Year-Over-Year growth rate of -11.59%. Revenue growth can be driven by product mix changes, market share expansion, price adjustments, or international market penetration. Investors should also monitor gross margin and regional revenue distribution for a comprehensive view of growth quality and sustainability.

  • How much debt does MRVI have?

    As of the end of the reporting period, Maravai lifesciences holdings, inc. (MRVI) had total debt of 321.91M, with a debt ratio of 0.87. Long-term debt comprises a higher/lower proportion. The level of financial leverage directly impacts the company's capital structure and interest coverage. If debt is high, pay attention to interest expenses and refinancing risks. Conversely, a low-leverage structure indicates greater risk tolerance but potentially less growth flexibility.

  • Does MRVI go with three margins increasing?

    In the latest report, Maravai lifesciences holdings, inc. (MRVI) did not achieve the “three margins increasing” benchmark, with a gross margin of 25.8%%, operating margin of -117.91%%, and net margin of -71.6%%. This demonstrates limited improvement in profitability, which is a key signal for fundamental analysis. Investors should consider margin trends alongside other financial indicators to assess MRVI's profit trajectory and future growth potential.

  • Is MRVI's EPS continuing to grow?

    According to the past four quarterly reports, Maravai lifesciences holdings, inc. (MRVI)'s earnings per share (EPS) shows a declining trend, with the latest EPS at -0.24. If EPS continues to rise due to revenue growth and cost optimization, it can support P/E valuation recovery and attract long-term investors.

  • What is the FCF of MRVI?

    Maravai lifesciences holdings, inc. (MRVI)'s Free Cash Flow (FCF) for the period is -24.88M, calculated as Operating Cash Flow minus Capital Expenditures, representing a fall of 32.57% compared with the previous period. Positive FCF growth provides stable funding for dividends, debt repayment, or strategic acquisitions, and is an important measure of true profitability and shareholder return potential.

  • What are the PEG ratio and PE ratio of MRVI?

    The latest valuation data shows Maravai lifesciences holdings, inc. (MRVI) has a Price-To-Earnings (PE) ratio of -7 and a Price/Earnings-To-Growth (PEG) ratio of -0.08. A PEG below 1 usually suggests the market is underestimating growth potential, while a PEG above 1 indicates high growth expectations are already priced in. Investors should conduct a comprehensive valuation by considering historical growth, market forecasts, and industry cycles.